Clinscience's owner takes majority stake in Florida-based CRO OncoBay
05 Jan 2023
ImmunotherapyClinical Study
Preview
Source: FierceBiotech
While Clinscience gets greater access to U.S. clinical trials and the regional biotech market, OncoBay will gain access to European clinical trials.
Poland-based Neuca Group, the parent company of CRO Clinscience, has taken a majority stake in Florida-based OncoBay to expand its reach in the U.S.
OncoBay, which is based in Tampa and was founded by the Moffit Cancer CenterCancer Center, is considered a "boutique" CRO that supports biotechs developing immuno-oncology therapies.
The investment, the financial terms of which weren't disclosed, gives Neuca a 72.6% stake in OncoBay, which has been collaborating with Clinscience for over two years. The two companies are currently working together to advance “several dozen” immuno-oncology projects, Clinscience said in a Jan. 4 press release.
“Our combined powers, supercharged by complementing competencies, proprietary technologies and streamlined organizational structure, set the stage for a full-scale global alternative in the clinical research market,” Clinscience CEO Tomek Dabrowski said in the release. “It allows us to further expand our abilities in cancer research, providing our clients with comprehensive support in their pursuit to develop innovative cancer treatments.”
While Clinscience gets greater access to U.S. clinical trials and the regional biotech market, OncoBay will gain access to European clinical trials, according to the release.
In November, oncology-focused OncoBay inked a deal to use physIQ’s latest patient monitoring system to track participants during their clinical trial journey in order to evaluate the effectiveness of treatments in near real time.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.